Is Nasus Pharma Ltd (NSRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.2% / 30% | 0.5% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 3.2% / 33% | 0.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 251.3% / 33% | 39.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 3.2% / 33% | 0.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 251.3% / 33% | 39.6% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -107.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$665,000 |
| Free Cash Flow | -$665,000 |
| Total Debt | $2M |
| Debt-to-Equity | 4.3 |
| Current Ratio | 2.2 |
| Total Assets | $717,000 |
Price & Trading
| Last Close | $2.40 |
| 50-Day MA | $4.94 |
| 200-Day MA | $6.71 |
| Avg Volume | 159K |
|
52-Week Range
$2.14
| |
About Nasus Pharma Ltd (NSRX)
Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Nasus Pharma Ltd (NSRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Nasus Pharma Ltd is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Nasus Pharma Ltd's debt ratio?
Nasus Pharma Ltd's debt ratio is 3.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 251.3%.
What are Nasus Pharma Ltd's key financial metrics?
Nasus Pharma Ltd has a market capitalization of $26M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.